Vault X Sideloaders - 9-Pocket Double-Sided A4 Trading Card Game Ring Binder Pages Storage Wallet - 11-Hole Side Loading Pockets for CCG TCG (50pc, Black)

£9.9
FREE Shipping

Vault X Sideloaders - 9-Pocket Double-Sided A4 Trading Card Game Ring Binder Pages Storage Wallet - 11-Hole Side Loading Pockets for CCG TCG (50pc, Black)

Vault X Sideloaders - 9-Pocket Double-Sided A4 Trading Card Game Ring Binder Pages Storage Wallet - 11-Hole Side Loading Pockets for CCG TCG (50pc, Black)

RRP: £99
Price: £9.9
£9.9 FREE Shipping

In stock

We accept the following payment methods

Description

If this card is the first card when the game begins, the player to the left of the dealer must skip their turn. 6. Reverse The Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicines, medical devices and blood components for transfusion in the UK. MHRA is an executive agency, sponsored by the Department of Health and Social Care. It is important that anyone who experiences new onset of symptoms such as chest pain, shortness of breath or feelings of having a fast-beating, fluttering, or pounding heart seeks medical attention. div class = "row row-cols-1 row-cols-md-2 g-4" > < div class = "col" > < div class = "card" > < img src = "..." class = "card-img-top" alt = "..." > < div class = "card-body" > < h5 class = "card-title" >Card title < p class = "card-text" >This is a longer card with supporting text below as a natural lead-in to additional content. This content is a little bit longer. < div class = "col" > < div class = "card" > < img src = "..." class = "card-img-top" alt = "..." > < div class = "card-body" > < h5 class = "card-title" >Card title < p class = "card-text" >This is a longer card with supporting text below as a natural lead-in to additional content. This content is a little bit longer. < div class = "col" > < div class = "card" > < img src = "..." class = "card-img-top" alt = "..." > < div class = "card-body" > < h5 class = "card-title" >Card title < p class = "card-text" >This is a longer card with supporting text below as a natural lead-in to additional content. < div class = "col" > < div class = "card" > < img src = "..." class = "card-img-top" alt = "..." > < div class = "card-body" > < h5 class = "card-title" >Card title < p class = "card-text" >This is a longer card with supporting text below as a natural lead-in to additional content. This content is a little bit longer. div class = "card text-center" > < div class = "card-header" > < ul class = "nav nav-pills card-header-pills" > < li class = "nav-item" > < a class = "nav-link active" href = "#" >Active < li class = "nav-item" > < a class = "nav-link" href = "#" >Link < li class = "nav-item" > < a class = "nav-link disabled" href = "#" tabindex = "-1" aria-disabled = "true" >Disabled < div class = "card-body" > < h5 class = "card-title" >Special title treatment < p class = "card-text" >With supporting text below as a natural lead-in to additional content. < a href = "#" class = "btn btn-primary" >Go somewhere Images

There is currently insufficient data to calculate a reliable estimate of the reporting rate in the UK due to the relatively limited exposure and small numbers of suspected reports in these individuals. div class = "card-group" > < div class = "card" > < img src = "..." class = "card-img-top" alt = "..." > < div class = "card-body" > < h5 class = "card-title" >Card title < p class = "card-text" >This is a wider card with supporting text below as a natural lead-in to additional content. This content is a little bit longer. < p class = "card-text" >< small class = "text-muted" >Last updated 3 mins ago < div class = "card" > < img src = "..." class = "card-img-top" alt = "..." > < div class = "card-body" > < h5 class = "card-title" >Card title < p class = "card-text" >This card has supporting text below as a natural lead-in to additional content. < p class = "card-text" >< small class = "text-muted" >Last updated 3 mins ago < div class = "card" > < img src = "..." class = "card-img-top" alt = "..." > < div class = "card-body" > < h5 class = "card-title" >Card title < p class = "card-text" >This is a wider card with supporting text below as a natural lead-in to additional content. This card has even longer content than the first to show that equal height action. < p class = "card-text" >< small class = "text-muted" >Last updated 3 mins ago The MHRA has received 30 UK reports of suspected ADRs with a fatal outcome to the bivalent COVID-19 Pfizer/BioNTech vaccine and 42 reports of suspected ADRs with a fatal outcome for the bivalent COVID-19 vaccine Moderna. The MHRA has received no UK reports with a fatal outcome for COVID-19 Vaccine Novavax. The game will always start with the light side. So when dealing cards, make sure that the dark side is facing you.

Cite this Entry

Over the course of the pandemic over 178,407 people across the UK have died within 28 days of a positive test for coronavirus (COVID-19). Vaccination is the single most effective way to reduce deaths and severe illness from COVID-19. A national immunisation campaign has been underway since early December 2020. International data has shown that these suspected events have been observed to occur most frequently approximately 3 days after the first vaccine and 2 days after the second vaccine, and both UK and international data have identified that the large majority of suspected events occur within 7 days of vaccination. In the UK the body of evidence shows that there is similar frequency of reporting after the first and second dose. The MHRA has undertaken a thorough review of both UK and international reports of suspected myocarditis and pericarditis following vaccination against COVID-19. There has been a consistent pattern of higher reporting of these suspected events with both the monovalent COVID-19 Vaccine Pfizer/BioNTech and COVID-19 Vaccine Moderna, and of these occurring more frequently in males. These reports have also been analysed by the government’s independent advisory body, the CHM and its COVID-19 Vaccines Benefit Risk Expert Working Group. Following their advice, the product information for both monovalent COVID-19 Vaccine Moderna and COVID-19 Vaccine Pfizer/BioNTech was updated to inform healthcare professionals and patients of these reports and provide advice to be aware of important symptoms for myocarditis and pericarditis. This advice has also been included in the product information for the bivalent (original/Omicron BA.1) COVID-19 vaccines for Moderna and Pfizer/BioNTech. Previous summaries of Yellow Card reporting covering the primary and Autumn 2021 booster vaccination campaigns presented tabulated summaries of reports with a fatal outcome stratified by vaccine brand, age and sex. With respect to the use of bivalent COVID-19 vaccines and the Autumn 2022 booster campaign these tables have now been replaced with an interactive search tool to allow readers to view the total number of reports with a fatal outcome received by the MHRA across the UK primary and booster vaccination programmes. The tool presents data by vaccine brand, age and sex with respect to these reports with a fatal outcome. On 15 August and 3 September 2022 respectively, the Moderna bivalent vaccine (Spikevax bivalent Original/Omicron BA.1) and the Pfizer/BioNTech bivalent vaccine (Comirnaty Original/Omicron BA.1) were approved by the MHRA as booster vaccines in those aged 12 years and above. Both bivalent vaccines are active against the original strain of the SARS-CoV-2 virus and the Omicron BA.1 variant. COVID-19 vaccine Novavax (Nuvaxovid), approved by the MHRA on 3 February 2022, and indicated for use in those aged 12 years and above is also being used as a booster dose in the small proportion of patients who are unable to receive mRNA vaccines.

The benefits of the vaccines in preventing COVID-19 and serious complications associated with COVID-19 far outweigh any currently known side effects in the majority of patients.From 1 September 2022 to 22 February 2023, the MHRA received and analysed 4,096 UK Yellow Cards from people who have received the bivalent COVID-19 Vaccine Pfizer/BioNTech. These reports include a total of 10,867 suspected reactions (i.e., a single report may contain more than one symptom).



  • Fruugo ID: 258392218-563234582
  • EAN: 764486781913
  • Sold by: Fruugo

Delivery & Returns

Fruugo

Address: UK
All products: Visit Fruugo Shop